X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BIO101 (20-hydroxyecdysone) is the first oral daily MAS receptor activator and has demonstrated metabolic effects on muscle and fat tissues. It is being evaluated for the treatment of obesity.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Nutrition and Weight Loss Product Name: BIO101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
Under the partnership, Skyepharma will develop finished product batches meeting the GMP standards of Sarconeos (20-hydroxyecdysone), an orally administered small molecule, for severe forms of Covid-19.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Infections and Infectious Diseases Product Name: Sarconeos
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Skyepharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 25, 2023
Details:
Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to significantly improve respiratory function in several preclinical models. It is being developed for treating severe forms of COVID-19.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Infections and Infectious Diseases Product Name: Sarconeos
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to significantly improve respiratory function in several preclinical models. It is being developed for treating sarcopenia.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Musculoskeletal Product Name: Sarconeos
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
Sarconeos (20-hydroxyecdysone) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to significantly improve respiratory function in several preclinical models. It is being developed for treating COVID-19.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Infections and Infectious Diseases Product Name: Sarconeos
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
The proceeds will fund research and development and clinical trials of its product canditates including, Sarconeos (BIO101), a small molecule in development for age-related neuromuscular (sarcopenia and Duchenne muscular dystrophy) and cardiorespiratory (Covid-19) diseases.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Infections and Infectious Diseases Product Name: Sarconeos
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $3.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 19, 2023
Details:
The agreement aims for the production of the active compound in Sarconeos (20-hydroxyecdysone), Biophytis' main drug candidate developed for three indications, severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Infections and Infectious Diseases Product Name: Sarconeos
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Seqens
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 18, 2023
Details:
Sarconeos (20-hydroxyecdysone) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to significantly improve respiratory function in several preclinical models. It is being developed for treating sarcopenia.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Musculoskeletal Product Name: Sarconeos
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
Sarconeos (BIO101, 20-hydroxyecdysone), is a small molecule, administered orally, a key component of the protective arm of the RAS, has shown positive results in the treatment of adult patients with a severe form of COVID-19.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Infections and Infectious Diseases Product Name: Sarconeos
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Intsel Chimos
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS, involved in the regulation of smooth, cardiac and skeletal muscle metabolism and plays a key role in muscle function and mobility. It is being developed for sarcopenia.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Musculoskeletal Product Name: BIO101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
